Your browser is no longer supported. Please, upgrade your browser.
MEIP MEI Pharma, Inc. monthly Stock Chart
MEI Pharma, Inc.
Index- P/E- EPS (ttm)-0.30 Insider Own3.00% Shs Outstand106.00M Perf Week-20.47%
Market Cap443.51M Forward P/E- EPS next Y-0.34 Insider Trans0.00% Shs Float99.79M Perf Month-11.63%
Income-24.50M PEG- EPS next Q0.22 Inst Own69.20% Short Float5.17% Perf Quarter134.25%
Sales4.50M P/S98.56 EPS this Y75.60% Inst Trans1.47% Short Ratio1.94 Perf Half Y48.70%
Book/sh0.70 P/B4.89 EPS next Y-580.00% ROA-27.60% Target Price- Perf Year48.70%
Cash/sh0.72 P/C4.78 EPS next 5Y-0.10% ROE-39.70% 52W Range0.72 - 4.46 Perf YTD37.90%
Dividend- P/FCF- EPS past 5Y29.50% ROI-96.50% 52W High-23.29% Beta1.95
Dividend %- Quick Ratio9.30 Sales past 5Y- Gross Margin27.50% 52W Low375.00% ATR0.38
Employees40 Current Ratio9.30 Sales Q/Q0.00% Oper. Margin- RSI (14)42.48 Volatility9.21% 8.66%
OptionableYes Debt/Eq0.00 EPS Q/Q83.20% Profit Margin- Rel Volume1.74 Prev Close3.49
ShortableYes LT Debt/Eq0.00 EarningsMay 07 BMO Payout- Avg Volume2.67M Price3.42
Recom1.70 SMA20-12.72% SMA500.76% SMA20049.29% Volume4,641,234 Change-2.01%
May-29-20Initiated SunTrust Buy $16
Dec-20-18Initiated H.C. Wainwright Buy $10
Dec-20-18Initiated H.C. Wainwright Buy
Jul-27-18Upgrade Stifel Hold → Buy $2.50 → $7
Jul-13-18Initiated SunTrust Buy $12
Apr-18-16Reiterated Wedbush Neutral $3 → $2
Mar-23-15Downgrade ROTH Capital Buy → Neutral $14 → $2.50
Dec-18-14Reiterated ROTH Capital Buy $22 → $14
Oct-16-14Reiterated ROTH Capital Buy $20 → $22
Jul-08-14Resumed Brean Capital Buy $16
Oct-22-13Reiterated Stifel Buy $11 → $15
Apr-15-13Initiated Stifel Buy $11
Jul-06-20 07:41PM  
Jul-03-20 10:50AM  
Jul-02-20 10:09PM  
Jun-29-20 11:31AM  
Jun-28-20 04:09PM  
Jun-23-20 08:18AM  
Jun-16-20 09:36AM  
Jun-12-20 08:53AM  
Jun-03-20 07:28AM  
Jun-02-20 08:40AM  
May-27-20 09:40AM  
May-26-20 08:00AM  
May-21-20 08:36AM  
May-15-20 11:25AM  
May-14-20 10:34AM  
May-13-20 05:05PM  
May-11-20 06:51AM  
May-09-20 10:25AM  
May-07-20 07:06AM  
Apr-20-20 10:55AM  
Apr-15-20 08:03AM  
Apr-14-20 01:00PM  
Apr-08-20 08:00AM  
Mar-31-20 08:00AM  
Mar-27-20 08:37AM  
Mar-26-20 07:44AM  
Mar-13-20 09:04AM  
Feb-18-20 09:46AM  
Feb-13-20 10:03AM  
Feb-06-20 04:02PM  
Dec-31-19 08:58AM  
Dec-29-19 09:40PM  
Dec-22-19 05:56PM  
Dec-19-19 11:45AM  
Dec-17-19 08:01AM  
Dec-16-19 04:01PM  
Dec-13-19 11:19AM  
Dec-09-19 01:25PM  
Nov-12-19 08:00AM  
Nov-07-19 04:05PM  
Oct-24-19 11:17AM  
Oct-04-19 07:32AM  
Oct-03-19 04:02PM  
Sep-23-19 08:00AM  
Sep-18-19 10:55AM  
Sep-14-19 01:34AM  
Aug-29-19 08:00AM  
Aug-28-19 04:05PM  
Aug-21-19 08:00AM  
Aug-13-19 11:56AM  
Jul-08-19 01:37PM  
Jul-03-19 08:00AM  
Jun-23-19 04:13PM  
Jun-22-19 02:30AM  
Jun-03-19 09:00AM  
Jun-01-19 09:00AM  
May-31-19 08:00AM  
May-15-19 05:00PM  
May-09-19 04:02PM  
May-01-19 10:32AM  
Apr-28-19 10:54AM  
Apr-12-19 04:52PM  
Apr-02-19 08:00AM  
Mar-12-19 08:00AM  
Feb-28-19 10:39AM  
Feb-07-19 04:05PM  
Jan-21-19 11:01AM  
Dec-03-18 01:32PM  
Dec-02-18 12:00PM  
Dec-01-18 12:00PM  
Nov-30-18 01:21PM  
Nov-19-18 08:10AM  
Nov-12-18 05:45AM  
Nov-08-18 04:00PM  
Nov-07-18 10:30AM  
Nov-06-18 08:00AM  
Nov-05-18 08:00AM  
Nov-02-18 08:37AM  
Nov-01-18 09:00AM  
Oct-11-18 06:42AM  
Sep-20-18 11:55AM  
Sep-10-18 03:21AM  
Aug-31-18 08:00AM  
Aug-30-18 04:05PM  
Aug-29-18 08:38AM  
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory follicular lymphoma and B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor for B-cell malignancies and AML. In addition, the company engages in the development of ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex for the treatment of HER2-negative breast cancer. MEI Pharma, Inc. has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacture, and commercialization of Pracinostat; and a license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor, as well as related compounds. The company also has a license agreement with CyDex Pharmaceuticals, Inc. for Captisol to use with ME-344, which are isoflavone-based drug compounds; a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of ME-401 in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies; and a license agreement with Kyowa Kirin Co., Ltd. for ME-401. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Reynolds Thomas CDirectorDec 19Buy1.6010,00016,00010,000Dec 20 12:57 PM
DRISCOLL FREDERICK WDirectorDec 19Buy1.6062,500100,00062,500Dec 20 12:56 PM
GOLD DANIEL P PHDChief Executive OfficerDec 19Buy1.6018,75030,000361,632Dec 20 12:54 PM
Drazba Brian G.Chief Financial OfficerDec 19Buy1.6012,50020,00037,500Dec 20 12:55 PM
GOLD DANIEL P PHDChief Executive OfficerSep 27Option Exercise1.5720,00031,400342,882Oct 01 12:04 PM
White Christine AnnaDirectorSep 06Buy1.7415,00026,07515,000Sep 09 04:52 PM